Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
Status:
Terminated
Trial end date:
2017-06-13
Target enrollment:
Participant gender:
Summary
The objectives of this study are twofold •To evaluate the safety and efficacy of 0.1%
AGN-195263 administered twice daily compared to its vehicle in patients with evaporative dry
eye (EDE) •To evaluate the systemic pharmacokinetics of 0.1% AGN-195263 administered twice
daily in patients with EDE